Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 29, 2025.

via HealthDay

TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a study published online July 23 in JAMA Surgery.

Laura S. Dominici, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined the long-term incidence of isolated LRR by molecular subtype in a multicenter prospective cohort study of women diagnosed with breast cancer at 40 years or younger from 2006 to 2016.

The cohort included 1,135 women with stage I through III breast cancer, with a median follow-up of 10.1 years. Age at diagnosis was younger than 30 years, 31 to 35 years, and 36 to 40 years for 12.8, 28.0, and 59.2 percent of patients, respectively. The researchers identified 59 isolated local recurrences and four isolated regional recurrences (5.2 and 0.4 percent, respectively). The cumulative incidence of LRR at 10.1 years by subtype was 4.4, 4.7, 6.1, 2.2, and 6.5 percent for luminal A, luminal B, luminal ERBB2+, ERBB2+, and triple-negative, respectively. The cumulative incidence of LRR at 10.1 years by locoregional treatment type was 6.7, 6.5, and 2.4 percent after breast-conserving therapy, mastectomy without radiation, and mastectomy with radiation, respectively. In a multivariable analysis, mastectomy with radiation was associated with the lowest risk for LRR, but no differences were seen when examined by molecular subtype.

"Reassuringly, in this large contemporary study of women diagnosed with breast cancer at age 40 years and undertreated with modern local and systemic therapy, we observed overall low rates of isolated LRR in long-term follow-up, with no significant differences by local therapy strategy when compared within tumor subtype," the authors write. "Given the lengthy survivorship period for young women with breast cancer and increased numbers of young women being diagnosed, even longer-term follow-up is critical for understanding future LRR risk in these patients."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-30 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords